Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Higher risk of secondary causes
This brief aims to highlight how patent abuse is a key tool enabling the pharmaceutical industry to carry out its financialized business model that perpetuates structural health inequities, particularly among communities of color
Why this matters for prediabetes and metabolic health GLP-1 medications serve as valuable tools for preventing diabetes and improving metabolic health
JAK inhibitors (tofacitinib, upadacitinib) offer oral convenience, whereas monoclonal antibodies (influx, miikizumab) are more advantageous in terms of mucosal healing and long-term remission
US$ 28.26
US$ 26.82
US$ 27.59
US$ 25.55
US$ 23.04
US$ 26.25
US$ 28.27
US$ 28.23
